Abstract

AN OVERVIEW OF SARCLISA DRUG

Komal Ugale*, Vaishnavi Kardile*, Yogita Sabale*, Prathmesh Katke*, Mr. Parkhe Kuldeepak R., Mr. Kote Prasad C., Mr. Nalawade Dipak D.

ABSTRACT

Sarclisa marked Sanofi's first wholly owned oncology approval since Jevtana in 2010. But when it landed the U.S. last year, Darzalex had been selling for nearly five years. Both drugs are anti-CD38 antibodies. In its short time on the market, Sarclisa reeled in $43 million in 2020 sales. Meanwhile, Darzalex got J&J $4.19 billion in global sales up40% year over year. OR Isatuximab (isatuximab -irfc; sarclisa ®) is an IgGI monoclonal antibody that binds to the glycoprotein CD38 expressed on the surface of haematopoietic and tumour cells. It is being developed by Sanofi, under a licence from immunogen, for the treatment of haematological malignancies. In March 2020, intravenous isatuximab was approved in the USA for the treatment of adult patients with multiple. Myeloma who have received> 2prior therapies including lenalidomide and a proteasome inhibitor. Isatuximab has also received a positive opinion in the EU for the treatment of relapsed and refractory multiple myeloma. This article summarises the milestones in the development of isatuximab leading to the first approval in the USA.

Keywords: .